Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		12 Months Ended
		Jun. 10, 2021 shares	Nov. 30, 2021 USD ($) shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares	Mar. 31, 2023 USD ($) shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares				156,005,891		166,884,802
Granted | shares				2,018,253
Weighted-average grant date fair values of options granted | $ / shares				$ 1.43	$ 2.44
Intrinsic value of vested options exercised | $				$ 200	$ 1,500
Unrecognized stock-based compensation cost | $				$ 57,900
Weighted average period over which unrecognized compensation is expected to be recognized				2 years 4 months 24 days
Stock-based compensation expense | $				$ 51,100	30,462
Issuance of common stock related to early exercise of stock options, shares | shares				180,718
Total liabilities | $				$ 195,709		$ 228,659
Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period			4 years
Unrecognized stock-based compensation cost | $				3,700
Weighted average period over which unrecognized compensation is expected to be recognized						2 years 3 months 18 days
Common stock granted subject to vest | shares			3,747,027
Common stock granted subject to vest, Weighted average grant date fair value | $			$ 43,900
General and Administrative [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				22,000
General and Administrative [Member] | Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				24,700	2,700
General and Administrative [Member] | Secondary Sale Transaction [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $	[1]			34,576	12,170
Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Tax benefit recognized from stock option exercises | $				0	0
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost | $				$ 136,300
Weighted average period over which unrecognized compensation is expected to be recognized				2 years 10 months 24 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vest, term				4 years
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vest, term				3 years
2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Available for Grant, Beginning balance | shares				22,839,019
Exercise price of stock options as a percentage of fair value of shares				110.00%
Share-based payment award, description				The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting in 2022, in an amount equal to (i) 22,839,019 shares of Class A common stock, (ii) 3.0% of the aggregate number of shares of Class A common stock and Class B common stock outstanding, or (iii) a lesser number of shares determined by the Company’s Board of Directors prior to the applicable January 1.
Share-based payment award, expiration period				10 years
Share-based compensation terms of award				Options under the 2021 Plan have a contractual life of up to ten years. The exercise price of a stock option shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the Board of Directors.
2021 Incentive Equity Plan [Member] | Stock Option Activity [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of total stock holding				10.00%
2021 Incentive Equity Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued and outstanding, percentage				3.00%
2021 Incentive Equity Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair value of shares				100.00%
ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock issued and outstanding, percentage		(1.00%)
Potential annual increase in shares reserved for future issuance | shares		5,000,000
2006 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted | shares				0
2022 AIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense | $				$ 4,400	$ 5,000
Other current liabilities | $				$ 5,500		$ 18,900
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		136,000,000
Exchange ratio of common stock				2.293698169
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Lemonaid Health, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares			2,990,386	139,656,589
Class A Common Stock [Member] | 2021 Incentive Equity Plan [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		136,000,000
Class A Common Stock [Member] | ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for future issuance | shares		11,420,000		16,349,302
Number of shares issued | shares				2,642,313
Class A Common Stock [Member] | 2022 AIP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock upon release of RSUs, shares | shares				8,961,053

[1] Includes $22.0 million of stock-based compensation expense related to the termination of a Former Lemonaid Officer during the three months ended June 30, 2023.